Clinical Trial

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Study acronym: DEMETHER
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
DEMETHER is a phase II trial exploring the maintenance of trastuzumab and pertuzumab fixed dose combination (FDC) for subcutaneous administration (SC, PHESGO) following trastuzumab deruxtecan (T-DXd) as induction treatment for HER2-positive unresectable locally recurrent or metastatic breast cancer (MBC) patients.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-12-06; most recent amendment 2026-04-28.
Status change: Recruiting → Active, Not Recruiting 2026-04-28
Status change: Not Yet Recruiting → Recruiting 2024-07-30
Trial Details
NCT Number NCT06172127
Lead Sponsor MedSIR
Collaborators: Hoffmann-La Roche
Conditions HER2-positive Breast Cancer
Enrollment 165 participants
Start Date 2024-07-22
Primary Completion 2027-04 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-29